Leahy B C, Honeybourne D, Brear S G, Carroll K B, Thatcher N, Stretton T B
Eur J Respir Dis. 1985 Jan;66(1):50-4.
Thirty two patients with malignant pleural effusion were randomly allocated to treatment with intrapleural Corynebacterium parvum or tetracycline hydrochloride in an attempt to prevent symptomatic recurrence of pleural fluid. Success in preventing recurrence of fluid at one month, using up to 2 doses of each drug, was 14 of 16 cases for Corynebacterium parvum, 5 of 9 for tetracycline given via an intercostal needle, and 6 of 7 for tetracycline given through an intercostal tube. These difference were not statistically significant. Corynebacterium parvum was significantly more likely to produce pyrexia equal or greater than 38 degrees C (P less than 0.001) and pain requiring analgesia (P less than 0.05) than tetracycline hydrochloride. Corynebacterium parvum is a useful agent for the management of malignant pleural effusion, but is associated with more side effects than tetracycline.
32例恶性胸腔积液患者被随机分配接受胸膜内注射短小棒状杆菌或盐酸四环素治疗,以试图预防胸腔积液症状复发。使用每种药物最多2剂,在1个月时预防积液复发的成功率为:短小棒状杆菌治疗的16例中有14例成功,经肋间针注射四环素治疗的9例中有5例成功,经肋间管注射四环素治疗的7例中有6例成功。这些差异无统计学意义。与盐酸四环素相比,短小棒状杆菌显著更易引起体温达到或高于38摄氏度的发热(P<0.001)以及需要镇痛的疼痛(P<0.05)。短小棒状杆菌是治疗恶性胸腔积液的一种有效药物,但与四环素相比副作用更多。